Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Major Shareholder Sells 426,005 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) major shareholder Rock Ventures L.P. Third sold 426,005 shares of the firm’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $40.32, for a total value of $17,176,521.60. Following the transaction, the insider owned 6,709,228 shares of the company’s stock, valued at $270,516,072.96. The trade was a 5.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Rapport Therapeutics Price Performance

Shares of NASDAQ:RAPP traded down $0.19 on Tuesday, hitting $36.95. 428,604 shares of the company traded hands, compared to its average volume of 331,850. Rapport Therapeutics, Inc. has a 52 week low of $7.73 and a 52 week high of $42.27. The stock has a 50 day simple moving average of $30.52 and a 200-day simple moving average of $28.63.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Tuesday, March 10th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.07). As a group, equities analysts expect that Rapport Therapeutics, Inc. will post -3.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on RAPP shares. Wall Street Zen downgraded Rapport Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a report on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, January 22nd. Raymond James Financial began coverage on Rapport Therapeutics in a report on Friday, April 10th. They issued a “strong-buy” rating and a $66.00 price objective for the company. Finally, Truist Financial upgraded Rapport Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $53.83.

Institutional Investors Weigh In On Rapport Therapeutics

Several large investors have recently bought and sold shares of the business. Strs Ohio increased its holdings in Rapport Therapeutics by 23.5% in the 3rd quarter. Strs Ohio now owns 2,100 shares of the company’s stock worth $62,000 after buying an additional 400 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Rapport Therapeutics by 56.9% in the 4th quarter. Russell Investments Group Ltd. now owns 2,282 shares of the company’s stock worth $69,000 after buying an additional 828 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Rapport Therapeutics by 64.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock worth $70,000 after buying an additional 905 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Rapport Therapeutics during the 4th quarter valued at about $37,000. Finally, Creative Planning grew its stake in shares of Rapport Therapeutics by 12.8% during the 3rd quarter. Creative Planning now owns 11,959 shares of the company’s stock valued at $355,000 after purchasing an additional 1,357 shares during the period.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.